This Is Not Just a Hospital Company Anymore

8,131 beds, India’s largest pharmacy network, a digital health platform and a merger that could reshape the pharmacy business 

There are healthcare businesses and there are healthcare platforms. Apollo Hospitals has spent the last several years quietly building the latter — a diversified ecosystem spanning hospital care, pharmacy distribution, digital health and retail diagnostics, each reinforcing the others and collectively creating a flywheel that is difficult for any single-segment competitor to replicate.

The Hospital Business 

Apollo’s hospital network operates 8,131 beds and is the foundation of the entire business. But what distinguishes Apollo’s hospital business from peers is not just scale — it is the quality and complexity of the care being delivered. CONGO specialties — cardiology, oncology, neurology, gastroenterology and organ transplants — account for 61% of hospital revenue. These are high-value, complex procedures where Apollo’s clinical depth, infrastructure and outcomes track record create genuine competitive advantage and command premium realisations.

Average revenue per patient — ARPP — reached Rs 178,434 in FY26, having grown at 8% CAGR over FY23-26. Antique expects ARPP to continue growing at 6% CAGR through FY28, supported by the continuing shift toward complex and high-value procedures. Occupancy, meanwhile, has improved 300 basis points over the same period and is expected to improve a further 120 basis points to above 68% by FY28 as recently commissioned hospitals ramp up and newer facilities come onstream.

The capacity expansion roadmap is substantial but phased intelligently. Apollo plans to add 3,415 operating beds over the next three to five years with planned capex of Rs 67 billion. Critically, only 29% of this new capacity is scheduled for commissioning in FY27, with the balance arriving in FY29-30 — a sequencing that prevents the margin dilution from premature capacity hitting the P&L all at once.

Near-term additions — hospitals in Sarjapur, Bengaluru and Gurugram — are expected to commission over the next two quarters, alongside the ramp-up of recently opened hospitals in Pune, Gachibowli, Sonarpur and Defence Colony. Antique expects the hospital segment to deliver EBITDA per bed reaching Rs 6.4 million by FY28, growing at 7% CAGR.

Apollo HealthCo 

At 43% of group revenue, Apollo HealthCo is the segment that most investors underweight relative to its strategic importance. It encompasses India’s largest organised retail pharmacy network — 7,289 stores — alongside pharmacy distribution and the Apollo 24|7 digital health platform. Together, these three elements give Apollo a presence across every channel through which Indians access medicines and healthcare products.

The transformational event in this segment is the proposed merger with Keimed — a move that Antique expects to be completed and listed by Q4FY27. The combined entity is targeting an annualised revenue run rate of Rs 250 billion with EBITDA margins of 6.5-7% by Q4FY27 — a scale that would make this one of the largest pharmacy businesses in Asia.

The integration of Apollo 24|7 with the merged entity is expected to drive higher online sales, an expanded private-label portfolio and significant supply chain synergies. Private label pharmacy products carry meaningfully better margins than third-party branded generics — and as the portfolio expands, the margin accretion compounds.

AHLL

Apollo Health and Lifestyle — primary care clinics, single-specialty services and diagnostics — contributes 7% of group revenue today but is expected to grow at the fastest rate of the three segments. After a restructuring phase in diagnostics, the business is emerging with improved economics and a cleaner operating model.

Antique forecasts AHLL revenue CAGR of 17% over FY26-28, with EBITDA margins expanding 230 basis points. Primary care, specialty care and diagnostics are expected to grow at 16%, 15% and 19% respectively — broad-based growth across all three formats that reflects genuine demand recovery rather than one sub-segment carrying the others.

The network expansion underway across AHLL’s healthcare delivery formats adds physical reach that feeds patients into the broader Apollo ecosystem — a diagnostics visit can become an Apollo 24|7 digital consultation, which can convert to a hospital admission for complex care. The flywheel is real, and AHLL is an increasingly important part of it.

The Sum-of-Parts 

Antique values Apollo on a sum-of-parts basis, which is the appropriate methodology for a business with three structurally distinct segments at very different stages of their maturity curves.

The stock currently trades at 23x FY28E EV/EBITDA — broadly in line with its five-year average of 22x. The BUY is not predicated on a re-rating but on earnings compounding — 24% PAT CAGR over FY26-28 on a business that is already profitable and cash-generative is the engine of the returns case.

The question worth asking about any large-cap healthcare stock is: what is the sustainable competitive advantage? For Apollo, the answer is layered. Clinical brand and outcomes data drive patient trust and referral networks that take decades to build — and Apollo has spent 40 years building them. The pharmacy network at 7,289 stores is the largest organised retail pharmacy footprint in India — a distribution asset that cannot be replicated quickly. The digital platform through Apollo 24|7, integrated with physical stores and hospitals, creates an omnichannel healthcare delivery capability that pure-play digital health companies cannot match and pure-play hospital companies cannot approach.

“Apollo Hospitals is among India’s largest private healthcare providers,” Antique’s report states — but the more important observation is that it is among the few that have built a genuinely integrated platform. That integration is what the Rs 9,790 target is underwriting.